You are viewing archived content
Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.
Figure GPS-18. Overview of drug prevalence estimates from various studies in Europe for all adults (aged 15 to 64) and young adults (aged 15 to 34) [see all figures in this series...]
Part (i) Cannabis use – lifetime experience, last year and last month prevalence
Notes:
The chart shows the overall average of the relevant studies, weighted by sample size.
Links:
SB2006: Figure GPS-33 part (i)
See also Table GPS-0 For details of the studies included see Tables GPS-1 to GPS-6
See also 'General notes for interpreting data' on the Explanatory notes and help page
Sources:
Reitox national reports 2006, taken from population surveys, reports or scientific articles.